Cargando…

Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations

OBJECTIVE: To examine characteristics of clinician input to the pan-Canadian Oncology Drug Review (pCODR) for cancer drug funding recommendations from 2016 to 2020. DESIGN, SETTING AND PARTICIPANTS: Descriptive, cross-sectional study including 62 reimbursement decisions from pCODR from 2016 to 2020....

Descripción completa

Detalles Bibliográficos
Autores principales:	Jenei, Kristina, Meyers, Daniel E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583055/ https://www.ncbi.nlm.nih.gov/pubmed/37844982 http://dx.doi.org/10.1136/bmjopen-2022-066378

Ejemplares similares

Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations
por: Binder, Louise, et al.
Publicado: (2022)

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
por: Chan, Kelvin, et al.
Publicado: (2020)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Role of healthcare cost accounting in pricing and reimbursement in low-income and middle-income countries: a scoping review
por: Guinness, Lorna, et al.
Publicado: (2022)

Refining the provider payment system of India’s government-funded health insurance programme: an econometric analysis
por: Prinja, Shankar, et al.
Publicado: (2023)

Examining the responsiveness of the National Health Insurance Fund to people living with hypertension and diabetes in Kenya: a qualitative study
por: Oyando, Robinson, et al.
Publicado: (2023)

Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives
por: Dane, Aniek, et al.
Publicado: (2022)

Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review
por: Janoudi, Ghayath, et al.
Publicado: (2016)

Two self-sampling strategies for HPV primary cervical cancer screening compared with clinician-collected sampling: an economic evaluation
por: Huntington, Susie, et al.
Publicado: (2023)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

A cost-benefit analysis of twice-daily consultant ward rounds and clinical input on investigation and pharmacy costs in a major teaching hospital in the UK
por: Ahmad, Aftab, et al.
Publicado: (2015)

Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR
por: Richter, Trevor, et al.
Publicado: (2018)

An Exploratory Analysis of Predictors of Concordance between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta
por: Zoratti, Michael J., et al.
Publicado: (2020)

Exploring the characteristics of the high-cost population from the family perspective: a cross-sectional study in Jiangsu Province, China
por: Miao, Yudong, et al.
Publicado: (2017)

Evidence-based recommendations for economic evaluations in spine surgery: study protocol for a Delphi consensus
por: Droeghaag, Ruud, et al.
Publicado: (2021)

Emigration-related attitudes of the final year medical students in Croatia: a cross-sectional study at the dawn of the EU accession
por: Kolčić, Ivana, et al.
Publicado: (2014)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
por: Zhu, Xingyue, et al.
Publicado: (2023)

Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy
por: Wilson, Mackenzie, et al.
Publicado: (2021)

Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system
por: Riva, Silvia, et al.
Publicado: (2021)

Observational study of the implementation of telephone advice nursing in Sweden: did callers follow recommendations and did the rate of healthcare visits change?
por: Sundberg, Amanda, et al.
Publicado: (2021)

Long-term fiscal implications of funding assisted reproduction: a generational accounting model for Spain
por: Matorras, R., et al.
Publicado: (2016)

Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
por: Ling, Kexin, et al.
Publicado: (2022)

Women’s preference to apply shared decision-making in breast cancer screening: a discrete choice experiment
por: Hernández-Leal, María José, et al.
Publicado: (2022)

Grow your investments with the best mutual funds and ETFs: making long-term investment decisions with the best funds today
por: Mckee, Stephen L
Publicado: (2015)

Patients’ perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review
por: Berglas, Sarah, et al.
Publicado: (2016)

Additional offer of sigmoidoscopy in colorectal cancer screening in Germany: rationale and protocol of the decision-analytic modelling approach in the SIGMO study
por: Diedrich, Leonie, et al.
Publicado: (2022)

Publicly insured caesarean sections in private hospitals: a repeated cross-sectional analysis in Chile
por: Borrescio-Higa, Florencia, et al.
Publicado: (2019)

Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples
por: Capozzi, Monica, et al.
Publicado: (2018)

Cost analysis of managing B3 breast lesions by vacuum excision at Leeds Breast Unit using a decision model
por: Yaziji, Nahel, et al.
Publicado: (2021)

Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey
por: Polisena, Julie, et al.
Publicado: (2017)

Planning human resources and facilities to achieve Sustainable Development Goals: a decision-analytical modelling approach to predict cancer control requirements in Indonesia
por: Melyda,, et al.
Publicado: (2022)

Caesarean sections and health financing: a global analysis
por: Hoxha, Ilir, et al.
Publicado: (2021)

Early invasive strategy in senior patients with non-ST-segment elevation myocardial infarction: is it cost-effective? - a decision-analytic model and value of information analysis
por: Simpson, Julija, et al.
Publicado: (2019)

King Edward's Hospital Fund for London Statistics
Publicado: (1914)

Using a discrete choice experiment to develop a decision aid tool to inform the management of persistent pain in pharmacy: a protocol for a randomised feasibility study
por: Loría-Rebolledo, Luis Enrique, et al.
Publicado: (2022)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Caesarean section in uninsured women in the USA: systematic review and meta-analysis
por: Hoxha, Ilir, et al.
Publicado: (2019)

Costs of childhood vaccine delivery in Iraq: a cross-sectional study
por: Garcia, Cristina, et al.
Publicado: (2022)

Cost–benefit analysis of surveillance for surgical site infection following caesarean section
por: Wloch, Catherine, et al.
Publicado: (2020)

The Statistical Report of King Edward's Hospital Fund. IV
Publicado: (1914)

Cannot write session to /tmp/vufind_sessions/sess_nbjtkp42bi4dt7ev3cnsreg29f